Several other research firms also recently issued reports on AMED. Raymond James upped their price target on Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Monday, July 15th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Barclays boosted their price objective on Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. Jefferies Financial Group set a $150.00 price objective on Amedisys and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, Royal Bank of Canada boosted their price objective on Amedisys to $150.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Amedisys currently has an average rating of “Buy” and a consensus price target of $135.90.
Shares of AMED traded down $3.65 during trading hours on Tuesday, hitting $126.44. 163,298 shares of the company were exchanged, compared to its average volume of 408,162. The company has a market cap of $4.19 billion, a PE ratio of 34.83, a PEG ratio of 1.95 and a beta of 1.42. The firm’s 50 day moving average is $131.01 and its 200-day moving average is $123.67. Amedisys has a 52 week low of $97.38 and a 52 week high of $141.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.88 and a current ratio of 0.88.
In other Amedisys news, insider Sharon Brunecz sold 1,050 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $136.28, for a total value of $143,094.00. Following the completion of the transaction, the insider now owns 11,480 shares of the company’s stock, valued at approximately $1,564,494.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Paul North sold 5,248 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $115.01, for a total value of $603,572.48. The disclosure for this sale can be found here. Insiders have sold a total of 51,427 shares of company stock valued at $6,298,052 in the last three months. 2.90% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in Amedisys by 23.4% in the 4th quarter. Geode Capital Management LLC now owns 429,999 shares of the health services provider’s stock valued at $50,357,000 after buying an additional 81,573 shares during the last quarter. Strs Ohio boosted its position in Amedisys by 1.7% in the 1st quarter. Strs Ohio now owns 11,700 shares of the health services provider’s stock valued at $1,442,000 after buying an additional 200 shares during the last quarter. Brinker Capital Inc. bought a new position in Amedisys in the 1st quarter valued at $229,000. Virginia Retirement Systems ET AL boosted its position in Amedisys by 14.7% in the 1st quarter. Virginia Retirement Systems ET AL now owns 10,900 shares of the health services provider’s stock valued at $1,344,000 after buying an additional 1,400 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its position in Amedisys by 38.3% in the 1st quarter. LS Investment Advisors LLC now owns 3,013 shares of the health services provider’s stock valued at $371,000 after buying an additional 835 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: Economic Reports
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.